Fig. 6From: Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatmentEffect of cisplatin and ACY-1083 on tau phosphorylation. Brains were collected after completion of behavioral tests and processed for immunofluorescence analysis of p-tau in the CA1 and DG regions. Mean fluorescence intensity was quantified. a–d, i Example images and quantification for p-tau staining in CA1 region from mice treated with (a) PBS + vehicle, (b) cisplatin + vehicle, (c) PBS + ACY-1083, or (d) cisplatin + ACY-1083 (n = 4; two-way ANOVA with Tukey’s post-hoc analysis: F(1, 12) = 22.85; PBS vs. Cisplatin, p = 0.0003; Cisplatin vs. Cisplatin + ACY-1083, p = 0.0002). e–h, j Example images and quantification for p-tau staining in DG region from mice treated with (e) PBS + vehicle, (f) cisplatin + vehicle, (g) PBS + ACY-1083, or (h) cisplatin + ACY-1083 (n = 4; two-way ANOVA with Tukey’s post-hoc analysis: F (1, 12) = 15.38; PBS vs. Cisplatin, p = 0.0002; Cisplatin vs. Cisplatin + ACY-1083, p = 0.0013). Results are expressed as means ± SEM; **P < 0.01, ***P < 0.001Back to article page